ADVANCED SOLID TUMORS

This early-phase trial tested a new oral drug (Debio 0123) combined with the chemotherapy carboplatin in 76 people with advanced solid tumors that had stopped responding to standard treatments. The goal was to find a safe dose and check for side effects. However, the study was te…

This early-phase trial tested an experimental cell therapy called HV-101 for people with advanced solid tumors that had come back or spread. The treatment involved removing immune cells from the patient's tumor, growing them in a lab, and infusing them back along with chemotherap…

This early-stage study tested a new oral drug, ATX-559, in 17 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to find a safe dose and check for side effects. The study was terminated early, so results are limited.

This early-phase study tested a new drug called ASP2074 in 23 adults with advanced solid tumors that had spread or could not be removed by surgery. The main goals were to find a safe dose and to see what side effects occur. The study was stopped early (terminated) by the sponsor.…

This early-stage study tested a new drug called VVD-130850, which blocks a protein (STAT3) that helps cancers grow. The trial aimed to find a safe dose and see if the drug works, both alone and with another immunotherapy, in people with advanced solid tumors or blood cancers. The…

This early-phase study tested an experimental drug called INCB081776, alone or combined with the immunotherapy retifanlimab, in 83 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find the right dose, and s…

This early-stage trial tested a new drug called 2X-121, alone and combined with another drug called dovitinib, in 14 people with advanced solid tumors. The goal was to find the safest dose and check for side effects. The study was terminated early, so results are limited and no c…

This early-phase study tested an experimental drug called INCA00186, alone or with other immunotherapy drugs, in 57 people with advanced solid tumors like head and neck or gastrointestinal cancers. The goal was to check safety, dosing, and early signs of effectiveness. The trial …

This study tested a new drug called ASP1570 in adults with advanced solid tumors that had spread or couldn't be removed. The drug aims to help the immune system fight cancer by stopping tumors from turning off immune cells. Participants received ASP1570 alone or with other cancer…

This early-phase study tested a new drug called FAZ053, either alone or with another drug (PDR001), in 154 adults with advanced solid tumors (including triple-negative breast cancer and certain sarcomas). The main goals were to check safety, find the right dose, and see how the b…

This early-stage study tested an experimental drug called INCB099318 in people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check the drug's safety and how the body processes it. The study was terminated early, so results are…

This study tested a new drug, BLU-222, for people with advanced solid tumors that had stopped responding to other treatments. The goal was to find a safe dose and see if it could shrink tumors. The study was ended early, so results are limited.

This early-phase study tested a new drug called BPT567 in 20 adults with advanced solid tumors that had stopped responding to standard treatments. The drug is designed to help the immune system fight cancer by targeting PD-1 and delivering an immune-boosting protein (IL-18). The …

This early-stage study tested a new drug called BAT8007 in 93 adults with advanced solid tumors that had not responded to standard treatments. The main goal was to check the drug's safety and find the right dose. The study was terminated early, so results may be limited.

This study tested a new experimental drug (BGB-30813) alone or combined with an immunotherapy (tislelizumab) in people with advanced solid tumors that had stopped responding to standard treatments. The goal was to find a safe dose and see if the drug could shrink tumors. The tria…

This early-stage trial tested a new drug called SIM0501, alone or with another drug (olaparib), in 13 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and how the drug moves through the body. The study was s…

This early-phase study tested an experimental drug (PF-07265028) alone or with another drug (sasanlimab) in 21 people with advanced solid tumors like lung, stomach, or bladder cancer. The goal was to find the safest dose and see if the drugs shrink tumors. The study was stopped e…

This study tested a new drug (INCB099280) combined with a standard cancer drug (axitinib) in adults with advanced solid tumors that had stopped responding to other treatments. The main goals were to check safety and see if the combination could shrink tumors. The trial was termin…

This early-stage study tested a new drug called Debio 0123 in 66 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to find the safest dose and to check for side effects and any signs that the drug could shrink tumors. The st…